Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07022483 · ClinicalTrials.gov registry record · Phase 3

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

A Phase 3 study of Endometrial Cancer, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 3
Development phase
710
Enrollment target
20
Study locations

NCT07022483: Recruiting Phase 3 study of Endometrial Cancer, sponsored by Daiichi Sankyo.

NCT07022483 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 710 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07022483, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 3
Development phase
710 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

Primary Outcome

Disease-Free Survival will be assessed radiographically by BICR or by histopathologic confirmation of disease recurrence per local assessment.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Chemotherapy
  • DRUG Trastuzumab Deruxtecan

Study Locations (20)

Other

  • Beijing Cancer Hospital - Beijing
  • The First Hospital of Jilin University - Changchun
  • West China Second University Hospital, Sichuan University - Chengdu
  • Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine - Hangzhou
  • Zhejiang Cancer Hospital - Hangzhou
  • Cancer Hospital of Shandong First Medical University - Jinan
  • Linyi Cancer Hospital - Linyi
  • Jiangxi Maternal and Child Health Hospital - Nanchang
  • Guangxi Medical University Affiliated Tumor Hospital - Nanning
  • Shanghai First Maternity and Infant HospitalShanghai First Maternity and Infant Hospital - Shanghai
  • Shanghai Tenth People's Hospital - Shanghai
  • Tianjin Medical University Cancer Institute & Hospital - Tianjin
  • The First Affiliated Hospital of Wenzhou Medical University - Wenzhou
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology - Wuhan
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan
  • Yantai Yuhuangding Hospital - Yantai
  • Hyogo Cancer Center - Akashi-shi

Florida

  • Mount Sinai Medical Center - Miami Beach

Louisiana

  • Trials365 LLC - Shreveport

South Dakota

  • Avera Medical Group Gynecologic Oncology Sioux Falls - Sioux Falls

Trial Details

FieldValue
Enrollment Target 710 participants
Start Date 2025-09-30
Est. Completion 2032-03-23
Phase Phase 3
Daiichi Sankyo

236 total trials

What NCT07022483 shows while recruiting

NCT07022483 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Chemotherapy is the first listed.

NCT07022483 names 20 study sites across 4 states, led by Other, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT07022483 about?

NCT07022483 is a clinical study titled "Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer". This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

What is the current status of trial NCT07022483?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2025-09-30. Estimated completion is 2032-03-23.

What conditions does trial NCT07022483 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT07022483?

The interventions under investigation include: Chemotherapy (DRUG), Trastuzumab Deruxtecan (DRUG).

Who is sponsoring clinical trial NCT07022483?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07022483 being conducted?

This trial has 20 study locations across Florida, Louisiana, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07022483's enrollment target sits among peer trials

710 20th of 181 higher than 161 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06179160 · 710 participants · Phase 1

    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  • NCT06235697 · 710 participants · Phase 3

    Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

  • NCT06470867 · 710 participants · NA

    Randomized Controlled Effectiveness Trial of VA S.A.V.E.

  • NCT06758401 · 714 participants · Phase 3

    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07022483

Source: ClinicalTrials.gov NCT07022483, the US trial registry maintained by the National Library of Medicine. NCT07022483 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.